Standard BioTools Inc.LABNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+62.5%
5Y CAGR+38.1%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+62.5%/yr
vs +30.6%/yr prior
5Y CAGR
+38.1%/yr
Recent acceleration
Acceleration
+31.9pp
Accelerating
Percentile
P97
Near historical high
vs 5Y Ago
5x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 94.61% |
| Q3 2025 | -7.42% |
| Q2 2025 | 31.75% |
| Q1 2025 | -115.40% |
| Q4 2024 | 49.55% |
| Q3 2024 | 28.63% |
| Q2 2024 | 37.50% |
| Q1 2024 | -344.32% |
| Q4 2023 | -23.21% |
| Q3 2023 | -22.33% |
| Q2 2023 | -9.95% |
| Q1 2023 | 55.76% |
| Q4 2022 | 22.06% |
| Q3 2022 | 17.93% |
| Q2 2022 | -92.35% |
| Q1 2022 | -122.65% |
| Q4 2021 | 26.25% |
| Q3 2021 | 35.26% |
| Q2 2021 | -13.67% |
| Q1 2021 | -245.59% |
| Q4 2020 | 18.83% |
| Q3 2020 | -64.84% |
| Q2 2020 | 35.04% |
| Q1 2020 | 22.18% |
| Q4 2019 | -21.35% |
| Q3 2019 | 9.28% |
| Q2 2019 | 75.10% |
| Q1 2019 | -3055.17% |
| Q4 2018 | 84.30% |
| Q3 2018 | 5.99% |
| Q2 2018 | 73.28% |
| Q1 2018 | -2547.20% |
| Q4 2017 | 108.28% |
| Q3 2017 | 3.73% |
| Q2 2017 | 2.33% |
| Q1 2017 | 20.83% |
| Q4 2016 | 18.97% |
| Q3 2016 | -79.92% |
| Q2 2016 | 5.62% |
| Q1 2016 | -78.43% |